21 maggio 2018

Strong uptake of RayStation Monte Carlo dose engine among proton therapy centers

13 out of 18 RayStation proton sites in clinical operation are now using the proton Monte Carlo (MC) dose engine, and this just a year after it was released. That according to a survey. “The implementation of the RayStation Monte Carlo dose engine has expanded our capability to serve more and a wider range of patients”, says Chang Chang, Director of Physics, Texas Center for Proton Therapy.

One year after RaySearch's first release of the proton MC dose engine in RayStation 6, a survey was sent out to the 18 RayStation proton sites that are in clinical operation with pencil beam scanning. The survey focused on the clinical implementation and use of the new MC dose engine. The answers showed that no less than 13 of the 18 clinics have implemented the MC dose engine in their clinical work flows, with remaining clinics currently in commissioning. Several clinics report that they use the MC dose engine for all patients, while others use it for selected cases where high accuracy is important, such as lung, brain, breast or head and neck.

Peer reviewed research papers are being published showing that Monte Carlo is now considered key for certain cancer types, which has prompted rapid implementation and acceptance. One prime example is “Pencil Beam Algorithms Are Unsuitable for Proton Dose Calculations in Lung”[1] .

Significantly, all clinics that have adopted MC for final dose computation, state that they also use it to drive the optimization. No significant deviations in the clinics validation studies have been reported. Also, all clinics mention very good results in the patient specific QA, especially for fields that employ a range shifter as compared to the results with the analytical dose engine.

Chang Chang, Director of Physics, Texas Center for Proton Therapy says: “The implementation of the RayStation Monte Carlo dose engine has expanded our capability to serve more and a wider range of patients. For example, it enabled us to use larger range shifter to patient air gaps, which streamlined our process in the treatment rooms. In addition, the higher accuracy of the Monte Carlo dose engine allowed us to treat sites like lung, complicated head and neck, and breast with more confidence."

Xavier Vermeren, Chief physicist, West German Proton Therapy Centre Essen says: “Now, when we find a rare deviation in our patient specific QA, we always double check our QA setup and data first. We simply expect the RayStation Monte Carlo dose to be correct, and we have yet to see a field that fails the QA."

Johan Löf, CEO of RaySearch, says: “We are extremely pleased to see that such a high fraction of our customers has implemented the Monte Carlo dose engine in a relative short time. It is also highly rewarding to learn how this new product has increased the quality of the treatments, while at the same time saving time for the physicists thanks to the improved QA results."

News

01/06/2018 News

New Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation

SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy&re [...]

30/05/2018 News

RaySearch and NIRS/QST, Japan, enter into collaboration agreement regarding ion beam therapy

RaySearch has signed a research collaboration and licensing agreement with the National Institutes for Quantum and Radiological Science and Technology (QST), a pioneer of ion beam technology based in Chiba, Japan. QST [...]

28/05/2018 Radioprotezione e QA

41° Corso della Scuola Preparatoria per l'Abilitazione degli esperti qualificati nella sorveglianza fisica della Radioprotezione SpEQu" , Bologna 10-12 ottobre 2018

Tecnologie Avanzate sarà sponsor del "41° Corso della Scuola Preparatoria per l'Abilitazione degli esperti qualificati nella sorveglianza fisica della Radioprotezione SpEQu" che avrà luogo in [...]

Eventi

20gen2017 | Eventi

RayCare Symposium, Roma 26 gennaio 2017

Tecnologie Avanzate è lieta di comunicare che il 26 gennaio organizza a Roma il primo RayCare Symposium, un incontro destinato a presentare in [...]

21giu2018 | Eventi

Corso base - Particle therapy, Pavia 21-22 giugno 2018

Tecnologie Avanzate sarà sponsor del "Corso base - Particle therapy" che avrà luogo a Pavia il 21-22 giugno 2018    

Video gallery